The incidence of Alzheimer’s Disease (AD) has reached epidemic proportions. More than 5 million Americans currently live with AD. While deaths from cardiovascular disease have fallen 14% since 2000, deaths from AD have increased by 89%. The cost of AD is projected to rise from $226 billion per year in 2015 up to $1.1 trillion in 2050. Approximately two-thirds of AD patients are women, and the diagnosis is often preceded by mild cognitive impairment (MCI). It’s believed that most patients suffer from MCI for at least 10 years prior to diagnosis and that the frequent dismissal of their symptoms by physicians and family leads to their missing a reasonable treatment window.
A concerned group of healthcare practitioners have embarked on the first rigorous trial of a very promising protocol designed to halt the progression of cognitive decline. We are calling this endeavor ReCODE or the Reversal of Cognitive Decline study. In the ReCODE trial we will employ Dr. Dale Bredesen’s ReCode Functional Medicine approach to reversing mild cognitive impairment and early dementia. You may be familiar with his book, The End of Alzheimer’s, which has been widely read and well-received. Our goal is that at least 25 people will complete the 9-month trial.
Our approach is to design a program for each study patient depending on their individual history, symptoms and a large set of laboratory data including digestive function and microbiome, nutrient and hormonal status, cardiovascular assessment, infectious etiologies, mold and chemical toxins and advanced genetic analysis. The study protocol involves the subjects adopting a specific diet, committing to regular exercise and working to optimize sleep, as well as learning to employ stress reduction techniques. Each patient will also be treated with individualized supplements and prescriptions where indicated, as well as treatment of any of the known dementia contributors that are uncovered.
Here is the detailed description from clinicaltrials.gov
The objective of the study was to determine if the ReCODE treatment has a measurable impact on the typical progression of neurocognitive decline observed in patients with Alzheimer's Disease (AD) and patients who are exhibiting Mild Cognitive Impairment (MCI). MCI is often a precursor to an AD diagnosis. Results of the study have been published here: ReCODE
This study successfully wrapped up in December of 2025. It was a randomized, controlled clinical trial using precision medicine, which is a novel approach involving comprehensive testing along with functional and lifestyle interventions for the treatment of mild cognitive impairment or early-stage dementia. This is a completely different way of looking at and treating memory loss that impacts so many.
This study followed 73 participants total who had mild cognitive impairment or early-dementia. Eligible participants were randomized into a 9-month precision medicine treatment approach or a 9-month standard treatment approach. The standard treatment approach group will have the option to receive up to six months of precision medicine treatment and testing at no cost following the completion of the trial. This trial was conducted at 6 sites across the nation: • Folsom, CA• San Rafael, CA• Walnut Creek, CA• Hollywood, FL• Rocky River, OH• Nashville, TN
Please click here to get to the PrePrint Writeup of the results!
Watch for peer reviewed results to be published in Spring 2026!